Recombinant lactic acid bacteria as mucosal biotherapeutic agents
Related Experiment Video
Updated: Jun 1, 2026

A Novel Method for the Culture and Polarized Stimulation of Human Intestinal Mucosa Explants
Published on: May 1, 2013
Catherine Daniel1, Yvonne Roussel, Michiel Kleerebezem
1Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Université Lille Nord de France, CNRS, UMR 8204, Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France. catherine.daniel@ibl.fr
Abstract:
The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.
Related Concept Videos
Probiotics
Microorganisms in Medicine and Therapeutics
Clinical Significance of Antibiotic Resistance
Microbiota Modulation by Antibiotics
Production of Organic Acids
Microbes in the Production of Fermented Foods
